Replies to post #102056 on Regen BioPharma Inc (RGBP)

[Jack Torrance]

Who knows. A merger would likely result in a complete restructure of the shares. Precigen is a Nasdaq company with only about 200 million shares.

I don't see Precigen buying Regen. Precigen only has a market cap of about $760 million. They don't have the money to buy Regen outright. The only thing that makes sense is a merger, where Regen is absorbed by Precigen and perhaps Regen shareholders are issued shares in the new combined company at a conversion rate. Maybe Regen adds about 100-200 million shares or so?--all of which are given to Regen shareholders in exchange for their current shares. If 100 million shares were added, that would be about a 1:40 conversion for Regen shareholders. Not too bad. But you would have shares in a Nasdaq cancer company with massive potential. The share price would probably pop anywhere from 3x-7x in a matter of a week, and then the sky would be the limit from there based on progress and clinical trials, etc...